NCT02907216View on ClinicalTrials.gov

Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants

PHASE4CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

May 29, 2017

Study Completion Date

May 29, 2017

Conditions
Rotavirus
Interventions
BIOLOGICAL

Squarekids

Three doses administered subcutaneously in the upper arm or thigh

BIOLOGICAL

Rotarix

Two doses administered orally

Trial Locations (11)

274-0063

GSK Investigational Site, Chiba

299-4503

GSK Investigational Site, Chiba

701-0205

GSK Investigational Site, Okayama

350-0001

GSK Investigational Site, Saitama

360-0018

GSK Investigational Site, Saitama

146-0095

GSK Investigational Site, Tokyo

157-0066

GSK Investigational Site, Tokyo

167-0052

GSK Investigational Site, Tokyo

183-0042

GSK Investigational Site, Tokyo

190-0023

GSK Investigational Site, Tokyo

206-0011

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02907216 - Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants | Biotech Hunter | Biotech Hunter